NEW YORK, March 15 – DeCode Genetics said Thursday its full-year 2000 revenue rose 30 percent to $21.5 million, compared with $16.6 million in 1999, due primarily to higher milestone payments stemming from the company’s research collaboration with Roche.

Of the $21.5 million, $10.1 million in revenues was recorded in the fourth quarter. However, DeCode did not report other figures on a quarterly basis.

For the year, DeCode recorded a 47 percent increase in total operating expenses to $61.1 million, as research and development and general and administrative costs rose.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.